Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Sells $28,194.09 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 1,409 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $20.01, for a total transaction of $28,194.09. Following the completion of the sale, the insider now directly owns 163,588 shares of the company’s stock, valued at approximately $3,273,395.88. This trade represents a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Natarajan Sethuraman also recently made the following trade(s):

• On Wednesday, November 13th, Natarajan Sethuraman sold 2,700 shares of Entrada Therapeutics stock. The stock was sold at an average price of $20.04, for a total transaction of $54,108.00.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.09, for a total value of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total transaction of $9,144.00.

Entrada Therapeutics Price Performance

Shares of NASDAQ:TRDA opened at $17.85 on Friday. The company has a market capitalization of $667.95 million, a price-to-earnings ratio of 11.23 and a beta of -0.26. The business’s 50-day moving average is $16.76 and its 200-day moving average is $15.92. Entrada Therapeutics, Inc. has a 1 year low of $10.75 and a 1 year high of $20.49.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.90. The company had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. Analysts anticipate that Entrada Therapeutics, Inc. will post 1.07 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC grew its holdings in shares of Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after purchasing an additional 13,742 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Entrada Therapeutics in the first quarter worth about $79,000. Bank of New York Mellon Corp lifted its position in Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after acquiring an additional 14,838 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Entrada Therapeutics by 25.3% during the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after acquiring an additional 7,452 shares during the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TRDA has been the subject of several research reports. Oppenheimer increased their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright boosted their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.